An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36107417/
doi: 10.1001/jamaoncol.2022.4175. Online ahead of print. 1 Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. 2 Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer...
Conclusions and Relevance: This review suggests that ERBB2-low may be a distinct, clinically relevant breast cancer entity warranting reassessment of traditional diagnostic and therapeutic paradigms. Ongoing clinical trials and further investigations may provide optimized strategies for diagnosing and treating ERBB2-low breast cancer, including...
Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36097254/
These real-world data complement clinical trial results by examining abemaciclib use among patients treated in routine clinical practice. The sizeable number of patients treated with prior CDK4 & 6i, chemotherapy,...
Conclusion: These real-world data complement clinical trial results by examining abemaciclib use among patients treated in routine clinical practice. The sizeable number of patients treated with prior CDK4 & 6i, chemotherapy, and/or visceral metastases at abemaciclib initiation suggest that many patients had very advanced disease and/or were...
Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
Providing evidence that there was no loss of efficacy by administering chemotherapy before surgery enabled investigators to exploit the huge translational research opportunities of the neoadjuvant setting. This in turn...
Relevance: In this article we review neoadjuvant clinical trials that guide optimum treatment options for TNBC and HR-positive, HER2-negative breast cancer.
-
Breast Cancer Connect3yrThanks for your input, Albert Dekker ! What new treatments do others suggest for TNBC and HR-positive, HER2-negative breast cancer?
-
Albert Dekker3yrfew compared newer agents against one the other
Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer
Source : https://ascopubs.org/doi/10.1200/JCO.22.00083
PURPOSE Despite the growing recognition of the importance of hypertension in patients with cancer, little is known about whether high blood pressure (BP) among patients with cancer is associated with...
Conclusion: Medication-naïve stage 1 and 2 hypertension was associated with a greater risk of HF and other CVD events in patients with cancer. Our results suggest the importance of multidisciplinary collaboration (eg, oncologists and cardiologists) to establish the optimal management strategy for hypertension in patients with cancer.
Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models
Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.915862/full
Cyclin-dependent kinases, CDK4 and CDK6, are essential in regulating the cell cycle, which is disrupted in cancers like isocitrate dehydrogenase wild-type glioblastoma (GBM). Currently marketed CDK4/6 inhibitors, including abemaciclib, have...
Conclusion/Relevance: These studies show possible BBB penetration of GLR2007 and demonstrate its potential as a CDK4/6 inhibitor for the treatment of solid tumors, including GBM.